✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
About · Methodology

Editorial Standards and the v4.1 Scoring Methodology

Released: Last reviewed:

How we read, date, score and correct every program on this site.

Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.
v4.1 methodology: seven weighted categories, 100 points (in use from October 15, 2026)
CategoryPointsWhat we check
Pricing transparency20Is every price published before intake, with plan length, billing basis and dose policy stated?
Total annual cost20What does 12 months cost at a maintenance dose, including membership, program and shipping fees?
Clinical oversight15Is a licensed clinician named, does a clinician review each intake, and is follow-up described?
Pharmacy transparency15Does the program name the pharmacy that fills prescriptions and its license type (503A or 503B)?
Support10Can patients reach a person, and are coaching or nutrition services described accurately?
Regulatory disclosure10Does the program say plainly when a drug is compounded and not FDA-approved?
Accessibility10Which states are served, which payment methods are accepted, and what are the cancellation terms?
Total100

How a score is built

Every score rests on the program’s own pages, read on a stated date and saved with the exact wording. If a page cannot be read, we say so and do not carry a figure forward as current. We do not use third-party star ratings, review counts or testimonials. Scores describe published terms and disclosures, not clinical outcomes, which no program publishes in a form we can verify.

Scoring guide: how each category is scored (published November 20, 2026)

These are the written rules behind every v4.1 score. Each rule is checked against the program’s own pages on the read date; anything we cannot see on those pages scores zero for that item. A program whose pages could not be read is not scored rather than scored zero.

v4.1 scoring guide: items and points per category
Category (points)Items and points
Pricing transparency (20)Medication-inclusive price for every plan length printed before intake: 8 (starting-dose or fee-only prices with medication priced separately: 4; fee only, no medication price: 2). Plan length and billing basis stated: 4 (partly or in conflict: 2). Dose policy stated (flat, or a price per dose): 4 (starting dose only or quantity caps: 2). No conflicting prices across the program’s pages: 4 (any conflict on the pages read: 2).
Total annual cost (20)Lowest 12-month cost at a maintenance dose for any GLP-1 the program sells, including required membership and program fees; brand-only programs add the manufacturer’s cash price for a maintenance dose (we use the Wegovy pill 25 mg at NovoCare’s $299). Up to $1,500: 20; $1,501–$2,000: 17; $2,001–$2,500: 14; $2,501–$3,500: 11; $3,501–$5,000: 8; over $5,000: 5. If only a starting-dose price is printed, or a plan’s supply falls short of a maintenance dose, the category is capped at 10. Twenty-eight-day cycles count as 13 a year. We use the cash-pay track and the lowest fee printed with a stated plan term.
Clinical oversight (15)A licensed clinician reviews each intake before prescribing: 5. Medical group, medical director or prescribing entity named: 5 (only “affiliated” or “independent” practices: 2). Ongoing follow-up described (check-ins, visits, messaging): 5 (vague: 2).
Pharmacy transparency (15)Dispensing pharmacy named: 10 (named but lists conflict: 8; some dispensing pharmacies named and others not, or license type only: 4; “licensed pharmacy” only: 2). License type (503A or 503B) stated: 5 (conflicting: 3). Programs that prescribe only FDA-approved brands, filled at a licensed pharmacy of the patient’s choice, earn full points.
Support (10)A human support channel with stated hours or 24/7: 5 (channels without hours: 3). Coaching, nutrition or dietitian support included: 5 (AI or community only: 2).
Regulatory disclosure (10)Says plainly that compounded drugs are not FDA-approved, or, for brand-only programs, names the FDA-approved products: 6 (footnote only: 3). No open FDA warning letter about the program’s own marketing in FDA’s index on the read date: 4.
Accessibility (10)States served stated: 4 (conflicting statements: 2; “not available in all states” without a list: 1). HSA/FSA or insurance accepted: 3. Cancellation terms stated (how and when): 3 (partly: 1).

Scores from pages read November 20, 2026

Ten GLP-1 programs were scored; Ro and Hims & Hers were not, because their sites returned HTTP 403 to our reads. NexLife has the highest computed score, so it ranks first on the computed result; there is no separate editorial placement. Equal totals are ordered by total-annual-cost points, then alphabetically. Each program’s review explains every point.

v4.1 scores by category, pages read November 20, 2026 (points; maximum in the header)
ProgramPricing (20)Annual cost (20)Clinical (15)Pharmacy (15)Support (10)Regulatory (10)Access (10)Total (100)
NexLife16201511106886
Eden Health2020124106678
Found201712957575
Sequence (WW Clinic)10815151010472
Mochi Health141012210101068
Form Health851515810667
LifeMD12812210101064
Calibrate1051015810664
Noom Med141110287456
Henry Meds141095310253
Ro BodyNot scored: ro.co returned HTTP 403 on November 20, 2026
Hims & HersNot scored: hims.com returned HTTP 403 on November 20, 2026

NexLife scored 94 on October 15, 2026, before this guide existed. Under the written rules it scores 86: it loses points because its own pages disagree on some prices, on multi-month billing, on how many pharmacies fill orders and on which states it serves, and because FDA warning letter 730096 (June 8, 2026) has no published close-out. Peptide and hormone clinics in our directory keep their May 2026 profiles under the older v3.0 rubric and are not part of this ranking.

Price claims

We never describe a program as the cheapest or lowest without a scope such as “among the programs we track” and a read date. Sale prices, prepaid prices and prices that require a membership are labelled with their condition.

Clinical evidence

Trial figures name the trial and the estimand, for example SURMOUNT-1 tirzepatide 15 mg: 20.9% average weight loss under the treatment-regimen estimand (22.5% under the efficacy estimand). Brand-drug trials do not describe compounded products, and no page on this site promises weight loss.

Source hierarchy

  1. Primary: program pricing and policy pages, FDA (warning letters, Drugs@FDA, compounding pages), the Federal Register, CMS, and peer-reviewed trials (NEJM, JAMA, The Lancet).
  2. Secondary: state licensing boards, the NPPES NPI Registry and company filings.
  3. Context only: press reports, marked “reported” until a primary source confirms them.

Ranking integrity

Who reviews the pages

Research and writing: Dr. Parmis, Medical Researcher, Western University of Health Sciences. Medical review: Dr. Jonathan Snipes, MD (NPI 1821250077) and Kim Callender, NP (FNP-BC, NPI 1144661760). Each page shows its release date, its last-reviewed date and the reviewers.

Update cadence

Prices are re-read in dated batches; pages whose content changes get a new “Last reviewed” date, and pages that still show older tables carry a dated notice. FDA actions and new trial results are added to the news page with their dates.

Corrections

Email americantelehealthreview@gmail.com with the page address, the claim and your evidence. We answer within 72 hours and publish warranted corrections on the corrections log.